Acute and chronic pain complaints, although common, are generally poorly served by
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …

There is a critical need for effective new pharmacotherapies for pain. The paucity of new
drugs successfully reaching the clinic calls for a reassessment of current analgesic drug …

Biomedical science has greatly improved our understanding of pain in recent decades, but
few novel molecular entities that address fundamentally new pain mechanisms have …

Despite intensive research into pain mechanisms and significant investment in research and
development, the majority of analgesics available to prescribers and patients are based on …

Opioid misuse and addiction are a public health crisis resulting in debilitation, deaths, and
significant social and economic impact. Curbing this crisis requires collaboration among …

Pain is the most common symptom for which patients seek medical attention. According to
the American Pain Society, prevalence of chronic pain in the United States is estimated to be …

The recent advances made in elucidating the processes of nociception have altered the way
that chronic pain therapy and analgesic drug development are approached. Recent studies …

The current gap between basic science research and the development of new analgesics
presents a serious challenge for the future of pain medicine. This challenge is particularly …

Neuropathic pain, caused by a lesion or disease affecting the somatosensory system, affects
between 3 and 17% of the general population. The treatment of neuropathic pain is …

Chronic neuropathic pain due to injury or dysfunction of the nervous system remains a
formidable treatment challenge in spite of a growing range of medication choices. We review …